Ingeborg Marianne Van Geijlswijk

Dr. Ingeborg Marianne Van Geijlswijk

Pharmacy, Utrecht University, Utrecht, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in SLEEP
Verified
Journal Article
Open access
PDF file
IGIngeborg Marianne Van Geijlswijk
Ingeborg Marianne Van Geijlswijk
HKHubert P. L. M. Korzilius
Hubert P. L. M. Korzilius
MSMarcel G. Smits
Marcel G. Smits
To perform a meta-analysis of the efficacy and safety of exogenous melatonin in advancing sleep-wake rhythm in patients with delayed sleep phase disorder. Meta analysis of papers indexed for PubMed, Embase, and the abstracts of sleep and chronobiologic societies (1990–2009). Individuals with delayed sleep phase disorder. Administration of melatonin. A meta-analysis of data of randomized controlled trials involving individuals with delayed sleep phase disorder that were published in English, compared melatonin with placebo, and reported 1 or more of the following: endogenous melatonin onset, clock hour of sleep onset, wake-up time, sleep-onset latency, and total sleep time. The 5 trials including 91 adults and 4 trials including 226 children showed that melatonin treatment advanced mean endogenous melatonin onset by 1.18 hours (95% confidence interval [CI]: 0.89–1.48 h) and clock hour of sleep onset by 0.67 hours (95% CI: 0.45–0.89 h). Melatonin decreased sleep-onset latency by 23.27 minutes (95% CI: 4.83 -41.72 min). The wake-up time and total sleep time did not change significantly. Melatonin is effective in advancing sleep-wake rhythm and endogenous melatonin rhythm in delayed sleep phase disorder.

1 July 2009 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
MHMichel Hoebert
Michel Hoebert
KHKristiaan B. Van Der Heijden
Kristiaan B. Van Der Heijden
IGIngeborg Marianne Van Geijlswijk
Ingeborg Marianne Van Geijlswijk
MSMarcel G. Smits
Marcel G. Smits

21 October 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MBMarian E. H. Bos
Marian E. H. Bos
FTFemke J. Taverne
Femke J. Taverne
IGIngeborg Marianne Van Geijlswijk
Ingeborg Marianne Van Geijlswijk
JMJohan W. Mouton
Johan W. Mouton
DMDik J. Mevius
Dik J. Mevius
DHDick J. J. Heederik
Dick J. J. Heederik
In 2011, Dutch animal production sectors started recording veterinary antimicrobial consumption. These data are used by the Netherlands Veterinary Medicines Authority to create transparency in and define benchmark indicators for veterinary consumption of antimicrobials. This paper presents the results of sector wide consumption of antimicrobials, in the form of prescriptions or deliveries, for all pig, veal calf, and broiler farms. Data were used to calculate animal defined daily dosages per year (ADDD/Y) per pig or veal calf farm. For broiler farms, number of animal treatment days per year was calculated. Furthermore, data were used to calculate the consumption of specific antimicrobial classes per administration route per pig or veal calf farm. The distribution of antimicrobial consumption per farm varied greatly within and between farm categories. All categories, except for rosé starter farms, showed a highly right skewed distribution with a long tail. Median ADDD/Y values varied from 1.2 ADDD/Y for rosé finisher farms to 83.2 ADDD/Y for rosé starter farms, with 28.6 ADDD/Y for white veal calf farms. Median consumption in pig farms was 9.3 ADDD/Y for production pig farms and 3.0 ADDD/Y for slaughter pig farms. Median consumption in broiler farms was 20.9 ATD/Y. Regarding specific antimicrobial classes, fluoroquinolones were mainly used on veal calf farms, but in low quantities: P75 range was 0 – 0.99 ADDD/Y, and 0 – 0.04 ADDD/Y in pig farms. The P75 range for 3rd/4th-generation cephalosporins was 0 – 0.07 ADDD/Y for veal calf farms, and 0 – 0.1 ADDD/Y for pig farms. The insights obtained from these results, and the full transparency obtained by monitoring antimicrobial consumption per farm, will help reduce antimicrobial consumption and endorse antimicrobial stewardship. The wide and skewed distribution in consumption has important practical and methodological implications for benchmarking, surveillance and future analysis of trends.

6 April 2009 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
PDF file
WBWiebe Braam
Wiebe Braam
MSMarcel G Smits
Marcel G Smits
RDRobert Didden
Robert Didden
HKHubert Korzilius
Hubert Korzilius
IGIngeborg Marianne Van Geijlswijk
Ingeborg Marianne Van Geijlswijk
LCLeopold M G Curfs
Leopold M G Curfs

1 September 2016 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
ADAlejandro Dorado-García
Alejandro Dorado-García
DMDik J. Mevius
Dik J. Mevius
JJJosé J. H. Jacobs
José J. H. Jacobs
IGIngeborg Marianne Van Geijlswijk
Ingeborg Marianne Van Geijlswijk
JMJohan W. Mouton
Johan W. Mouton
DHDick J. Heederik
Dick J. Heederik
To quantify associations between antimicrobial use and acquired resistance in indicator Escherichia coli over a period of time which involved sector-wide antimicrobial use reductions in broilers and pigs (years 2004–14), veal calves (2007–14) and dairy cattle (2005–14). Prevalence estimates of resistance were predicted for a hypothetical further decrease in antimicrobial use. Data reported annually for the resistance surveillance programme in the Netherlands were retrieved. Two multivariate random-effects logistic models per animal sector were used to relate total and class-specific antimicrobial use (as defined daily dosages per animal per year, DDDA/Y) with the probability of E. coli resistance to a panel of 10 antimicrobial agents. Positive dose–response relationships (ORs) were obtained from all models. Specific resistance phenotypes were more often associated with total antimicrobial use than with class-specific use. The most robust associations were found in pigs and veal calves. Resistance to historically widely used antimicrobials (e.g. penicillins, tetracyclines) was, in relative terms, less influenced by drug use changes over time than resistance to newer or less prescribed antimicrobials (e.g. third-/fourth-generation cephalosporins, fluoroquinolones). In pigs and veal calves, prevalence estimates for the most common resistance phenotypes were projected to decline ∼5%–25% during 2014–16 if total antimicrobial use reduction reached 80%; projections for poultry and dairy cows were more modest. Epidemiological evidence indicated that drug use history and co-selection of resistance are key elements for perpetuation of resistance. Data suggest that recent Dutch policies aimed at reducing total use of antimicrobials have decreased E. coli resistance in the pig and veal calf production sectors while the impact on the dairy cattle and poultry sectors is less clear.

29 July 2010 in Psychopharmacology
Verified
Journal Article
Open access
PDF file
IGIngeborg Marianne Van Geijlswijk
Ingeborg Marianne Van Geijlswijk
KHKristiaan B. van der Heijden
Kristiaan B. van der Heijden
AEA. C. G. Egberts
A. C. G. Egberts
HKHubert P. L. M. Korzilius
Hubert P. L. M. Korzilius
MSMarcel G. Smits
Marcel G. Smits
Rationale Pharmacokinetics of melatonin in children might differ from that in adults. Objectives This study aims to establish a dose–response relationship for melatonin in advancing dim light melatonin onset (DLMO), sleep onset (SO), and reducing sleep onset latency (SOL) in children between 6 and 12 years with chronic sleep onset insomnia (CSOI). Methods The method used for this study is the randomized, placebo-controlled double-blind trial. Children with CSOI (n = 72) received either melatonin 0.05, 0.1, and 0.15 mg/kg or placebo during 1 week. Sleep was assessed with log and actigraphy during this week and the week before. Outcomes were the shifts in DLMO, SO, and SOL. Results Treatment with melatonin significantly advanced SO and DLMO by approximately 1 h and decreased SOL by 35 min. Within the three melatonin groups, effect size was not different, but the circadian time of administration (TOA) correlated significantly with treatment effect on DLMO (r s = −0.33, p = 0.022) and SO (r s = −0.38, p = 0.004), whereas clock TOA was correlated with SO shift (r = −0.35, p = 0.006) and not with DLMO shift. Conclusions No dose–response relationship of melatonin with SO, SOL, and DLMO is found within a dosage range of 0.05–0.15 mg/kg. The effect of exogenous melatonin on SO, SOL, and DLMO increases with an earlier circadian TOA. The soporific effects of melatonin enhance the SO shift. This study demonstrates that melatonin for treatment of CSOI in children is effective in a dosage of 0.05 mg/kg given at least 1 to 2 h before DLMO and before desired bedtime.